Ponatinib Plus Hyper-CVAD Active as Frontline Therapy in Ph+ ALL

Slideset - In this phase II open-label study, the combination of ponatinib with hyper-CVAD resulted in high complete cytogenetic and molecular response rates in patients with Ph+ ALL.

Source: Clinical Care Options Leukemia - December 12, 2016 Category: Hematology Source Type: research